

University of Montana

ScholarWorks at University of Montana

University of Montana Conference on Undergraduate Research (UMCUR)

Apr 22nd, 3:00 PM - 4:00 PM

Cough Desensitization Treatment: Combination of Desensitization and Cough Suppression

Sophia E. Tolbert

University of Montana, Missoula, st138764@umconnect.umt.edu

Paige Morkid

University of Montana, Missoula, pm252831@umconnect.umt.edu

Jane Reynolds

University of Montana, Missoula, jr145900@umconnect.umt.edu

Follow this and additional works at: <https://scholarworks.umt.edu/umcur>

Let us know how access to this document benefits you.

Tolbert, Sophia E.; Morkid, Paige; and Reynolds, Jane, "Cough Desensitization Treatment: Combination of Desensitization and Cough Suppression" (2022). *University of Montana Conference on Undergraduate Research (UMCUR)*. 4.

<https://scholarworks.umt.edu/umcur/2022/pm posters/4>

This Poster is brought to you for free and open access by ScholarWorks at University of Montana. It has been accepted for inclusion in University of Montana Conference on Undergraduate Research (UMCUR) by an authorized administrator of ScholarWorks at University of Montana. For more information, please contact scholarworks@mso.umt.edu.




Cough Desensitization Treatment: Combination of Desensitization and Cough Suppression

Sophia Tolbert, Jane Reynolds, Paige Morkid, Shannon Welby
 Faculty Mentor: Laurie Slovrap, PhD, CCC-SLP

Introduction/Objective

Chronic cough (CC), a cough that persists longer than 8 weeks, impacts 11% of Americans. 15-20% do not respond to standard medical treatment and are diagnosed with refractory chronic cough (RCC). Most of these patients suffer from RCC due to hypersensitivity of airway sensory nerves. The objective of this study is to assess validity of a new treatment for RCC called cough desensitization treatment (CDT). CDT involves exposing patients to aerosolized capsaicin, a known cough stimulant found within chili peppers, in increasing doses while actively suppressing cough.

Methodology




Conclusion

The use of capsaicin to desensitize the airway paired with behavioral cough suppression therapy is a promising treatment for those with chronic cough. 8 out of 10 patients in the treatment group had clinically significant improvement in their LCQ, with two patients improving by 10+ points. There is strong evidence that there was greater improvement in the treatment group's cough-reflex threshold compared to the placebo group. This means that the treatment group was more desensitized at post-test 1 and could withstand more capsaicin. The mean VAS change reported in the treatment group was four times greater than that reported in the placebo group, with large effect sizes. There is strong evidence to show that the placebo group improved as well. We are unsure of this is due solely to placebo effects or if it is a possible treatment effect.

Results/Analysis

A one-way analysis of covariance (ANCOVA), with baseline scores as the covariate, was used to evaluate the group mean differences in LCQ scores and cough sensitivity (i.e., logC5) at post-test 1. There was not a statistically significant difference in LCQ scores between the groups ($p=.67$ partial $\eta^2=.012$), but there was a statistically significant difference between the groups on logC5 ($p=.01$ partial $\eta^2=.36$) with a large effect size. Assumptions for a one-way ANCOVA were not met for the VAS data so an independent samples t-test comparing change in group means was run. The difference in VAS scores between the treatment and placebo groups neared statistical significance ($p=.055$, partial $\eta^2=.983$) with a very large effect size.



Future Directions

Plans for a multi-site study trial with the University of Colorado, Emory University, and the University of Utah are underway.